Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation

Post-hoc subgroup analysis of the negative trial of interleukin-1β receptor antagonist (IL1RA) for septic shock suggested that patients with features of macrophage activation syndrome (MAS) experienced a 50% relative risk reduction for mortality with treatment. Here we seek a genetic basis for this...

Descripción completa

Detalles Bibliográficos
Autores principales: Kernan, Kate F., Ghaloul-Gonzalez, Lina, Shakoory, Bita, Kellum, John A., Angus, Derek C., Carcillo, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320733/
https://www.ncbi.nlm.nih.gov/pubmed/29977033
http://dx.doi.org/10.1038/s41435-018-0030-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320733/
https://www.ncbi.nlm.nih.gov/pubmed/29977033
http://dx.doi.org/10.1038/s41435-018-0030-3

Ejemplares similares